Palmitoylethanolamide - Prismic Pharmaceuticals

Drug Profile

Palmitoylethanolamide - Prismic Pharmaceuticals

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator Epitech Group
  • Developer Prismic Pharmaceuticals
  • Class Anti-inflammatories; Cannabinoids; Ethanolamines; Neuroprotectants; Palmitic acids
  • Mechanism of Action Cannabinoid receptor agonists; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Pain
  • Preclinical Inflammation

Most Recent Events

  • 11 Feb 2015 palmitoylethanolamide - Prismic Pharmaceuticals is available for licensing in World as of 13 Aug 2013.
  • 03 Feb 2015 Preclinical trials in Inflammation in USA (unspecified route)
  • 03 Feb 2015 Clinical trials in Pain (Combination therapy) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top